U.S. Luxury Stock News

NYSE:GNL
NYSE:GNLREITs

Can Global Net Lease (GNL) Stay Cheap After Its $535 Million Deal?

Global Net Lease has delivered a strong 31.1% one year return, yet current valuation work suggests the stock may still trade below its estimated intrinsic value based on a Discounted Cash Flow (DCF) view and market multiples. Over the last 12 months, Global Net Lease has returned 31.1%, which puts fresh focus on whether the recent share price better reflects the underlying real estate portfolio. The acquisition of Modiv Industrial for US$535 million can support long term rental income from...
NYSE:IVZ
NYSE:IVZCapital Markets

US Treasury Turmoil Could Reshape Invesco SEI And Acadian Stock Outlook

Long dated US Treasuries are back in the spotlight as Washington leans on buybacks and even the Treasury General Account to steady bond markets, while critics question what that means for long term yields and risk premia. For investors, that mix of policy experimentation and credibility concerns can reshuffle the winners and losers among US bond trading and fixed income market making banks. This article walks through three stocks from our screener that appear most exposed to this story and...
NasdaqGM:APPF
NasdaqGM:APPFSoftware

AppFolio (APPF) AWS Tie Up Puts Its Valuation Back In Focus

AppFolio’s AWS partnership and why it matters for investors AppFolio (APPF) recently named Amazon Web Services as its preferred cloud provider, formalising a collaboration that underpins its AI native Performance Platform and the Realm suite for nearly 23,000 real estate customers. See our latest analysis for AppFolio. AppFolio’s AWS announcement lands after a strong run in the share price, with a 30 day share price return of 36.38% and a 90 day share price return of 37.45%. However, the 1...
NYSE:ENVA
NYSE:ENVAConsumer Finance

Upstart Stock And Other Nonbank Lenders Facing A Fed Credit Reset

Monetary policy is back in the spotlight, with a push to shift the Federal Reserve away from interest rate targeting and toward strict control of credit growth. That kind of rule based approach could reshape how money flows through lenders and into the real economy, which matters for future borrowing costs and credit availability. This article walks through three U.S. nonbank and fintech lenders exposed to that debate, and explains how this policy rethink could influence their risk and reward...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia Pharmaceuticals (AUPH) Is Up 8.4% After Teva Agrees To Delay Generic Voclosporin Launch

Aurinia Pharmaceuticals recently entered into a settlement with Teva Pharmaceuticals resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin capsules, with Teva agreeing that Aurinia’s patents, expiring in December 2037, are valid, enforceable, and would be infringed by U.S. sales of its generic. The agreement, which restricts Teva from launching its generic voclosporin in the U.S. before December 7, 2036 (subject to contingencies and FDA approval), materially...
NYSE:EFOR
NYSE:EFORIT

Everforth (EFOR) Lands A $30 Million DHA Contract, Is The Rebound Already Fully Priced?

Everforth (EFOR) stock is in focus after its ECS unit secured a four year, US$30 million prime contract with the Defense Health Agency to support data driven IT modernization and analytics. See our latest analysis for Everforth. The recent four year Defense Health Agency contract has arrived during a sharp rebound in Everforth’s share price, with a 30 day share price return of 57.77% and a 90 day share price return of 68.74%. However, the 1 year total shareholder return is still down 38.59%...
NYSE:AZO
NYSE:AZOSpecialty Retail

AutoZone (AZO) Gains Attention Ahead Of Earnings, Is It 24% Undervalued?

AutoZone (AZO) has drawn fresh attention after its stock gained 1.74% on a weak market day, as investors focus on the company’s upcoming fourth quarter fiscal 2026 earnings and related conference call. See our latest analysis for AutoZone. That 1.74% one day share price gain comes after a mixed run for AutoZone, with the 30 day share price return of 1.76% set against a year to date share price decline of 8.91% and a 1 year total shareholder return that declined 27.31%, while the 5 year total...
NYSE:BAP
NYSE:BAPBanks

Can Credicorp (BAP) Justify Its Valuation As Earnings Rise In Q2 And H1?

Credicorp (NYSE:BAP) has drawn investor attention after reporting its second quarter and first half 2026 results. The company showed higher net interest income, net income and earnings per share than in the same periods last year. See our latest analysis for Credicorp. Credicorp's recent earnings release comes after a strong run, with a year to date share price return of 32.59% and a 1 year total shareholder return of 58.00%. The 3 year and 5 year total shareholder returns of 217.40% and...
NasdaqGS:SCSC
NasdaqGS:SCSCElectronic

Why ScanSource (SCSC) Is Up 7.5% After Earnings Beat, 2027 Guidance And Board Refresh

ScanSource, Inc. has already reported full-year results for the period ended June 30, 2026, with sales rising to US$3.23 billion and net income improving to US$78.87 million, alongside higher basic and diluted earnings per share from continuing operations. Alongside these results, ScanSource issued guidance for fiscal 2027 calling for mid‑single‑ to high‑single‑digit net sales growth, while its Board adjusted to seven members following the retirement of long‑serving director Peter C...
NYSE:GDDY
NYSE:GDDYIT

GoDaddy (GDDY) Faces Class Action Over Discount Disclosures Is Management’s Credibility Now in Question?

In August 2026, Kaplan Fox & Kilsheimer LLP filed a past shareholder class action in the Southern District of New York against GoDaddy Inc., alleging that between September 3, 2025 and February 24, 2026 the company misled investors about its customer growth strategy and the impact of 2025 promotional discounts on bookings. The complaint centers on an alleged mismatch between GoDaddy’s public comments about rising average order size and an internal push for short-term, lower-value contracts...
NYSE:IFF
NYSE:IFFChemicals

Did GLP-1-Driven Appetite Shifts in India Just Reframe International Flavors & Fragrances' (IFF) Investment Narrative?

Earlier this month, International Flavors & Fragrances released its “Inside the India GLP-1 Consumer Journey” report, detailing how GLP-1 usage is reshaping Indian consumers’ eating habits, nutrition priorities, and sensory preferences. The research points to consumers favoring smaller portions but higher-quality, better-tasting foods, signaling emerging product innovation opportunities for food and beverage brands that work with IFF. We’ll now explore how IFF’s insights into GLP-1-driven...
NYSE:PPL
NYSE:PPLElectric Utilities

How Investors May Respond To PPL (PPL) Dividend And Planned US$23 Billion Grid Investment Program

PPL Corporation previously declared a quarterly common stock dividend of US$0.2850 per share on August 21, 2026, payable on October 1, 2026, to shareowners of record as of September 10, 2026. Alongside this dividend, PPL outlined nearly US$5.10 billion of 2026 capital investments and US$23.00 billion through 2029, signaling a sizable commitment to grid and infrastructure spending backed by expanding revenues. We will now explore how PPL’s large multi‑year capital investment program could...
NYSE:ASH
NYSE:ASHChemicals

Ashland’s New Oral Biologics Excipient Launch Might Change The Case For Investing In Ashland (ASH)

Ashland Inc. recently launched permexa sodium caprate, an intestinal permeation enhancer engineered to support scalable oral peptide, biologic and low-permeability drug products, including GLP-1 therapies. The product’s blend of permeability enhancement with improved powder flow and tablet compressibility offers a differentiated excipient solution for complex oral biologic formulations and manufacturing. We’ll now explore how Ashland’s permexa sodium caprate launch, aimed at oral biologics...
NYSE:BXP
NYSE:BXPOffice REITs

Did BXP’s (BXP) Upbeat Q2 Beat and Higher FFO Outlook Just Shift Its Investment Narrative?

On July 28, 2026, BXP reported second-quarter results that exceeded analyst expectations and raised the midpoint of its full-year 2026 FFO outlook, citing improving business fundamentals. This combination of stronger-than-anticipated earnings and a higher FFO forecast highlighted management’s increased confidence in the company’s operating trajectory and cash flow visibility. Next, we’ll examine how BXP’s upgraded full-year FFO outlook shapes its existing investment narrative and risk‑reward...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Legend Biotech Corporation recently reported its second-quarter 2026 results, with revenue rising to US$387.5 million from US$255.1 million and net income turning to US$33.2 million from a net loss of US$125.4 million a year earlier. Over the first half of 2026, revenue increased to US$692.6 million while the company sharply reduced its net loss to US$21.1 million, highlighting a rapid improvement in profitability metrics. With Legend Biotech’s latest quarter showing a shift to...
NYSE:NNN
NYSE:NNNRetail REITs

Why NNN REIT (NNN) Is Back In The Spotlight

NNN REIT (NNN) drew fresh attention after appointing Christina Chiu and Charles D. Mueller Jr. to its Board of Directors, a planned succession move related to the forthcoming retirement of director Betsy D. Holden. See our latest analysis for NNN REIT. Alongside the board refresh, NNN REIT’s recent 1-day share price return of 1.11% and year to date share price return of 17.23% come after a 30 day share price decline of 6.16%. Its 1-year total shareholder return of 16.62% and 5-year total...
NasdaqGM:PRCT
NasdaqGM:PRCTMedical Equipment

Is Alleged Bulk Discounting And Inventory Build Altering The Investment Case For PROCEPT BioRobotics (PRCT)?

In recent months, multiple law firms have filed securities class action lawsuits against PROCEPT BioRobotics, alleging undisclosed bulk discounting of Aquablation handpieces that inflated reported unit sales, revenues, and key utilization metrics. The core allegation is that these discount-driven bulk orders pulled demand forward and led to excess customer inventory, raising questions about the sustainability and quality of PROCEPT’s previously reported growth indicators. We’ll now examine...
NasdaqGS:WMG
NasdaqGS:WMGEntertainment

Warner Music Group (WMG) After AI Lawsuit Exit Has Valuation Back In Focus

The American Federation of Musicians has dropped its AI compensation lawsuit against Warner Music Group (WMG), shifting the remaining case to Warner Records as broader talks on generative AI and musician pay continue. See our latest analysis for Warner Music Group. The legal overhang easing for Warner Music Group comes as the stock trades at US$27.76, with a 7 day share price return of 5.27% but a 1 year total shareholder return that has declined 16.4%, pointing to recent momentum after a...
NYSE:YELP
NYSE:YELPInteractive Media and Services

Yelp (YELP) Draws Fresh Valuation Attention, Is The 10% Undervaluation Case Convincing?

Yelp (YELP) has drawn fresh attention after its recent share price move, with the stock closing at US$23.83. Investors are weighing this valuation against the company’s latest revenue and net income figures. See our latest analysis for Yelp. Looking beyond the latest move, Yelp’s recent trading tells a mixed story. The stock has a 7 day share price return of 3.29% and a 90 day share price return of 3.92%, yet the year to date share price return is down 21.09%, and the 1 year total shareholder...
NYSE:MCO
NYSE:MCOCapital Markets

Is Moody's (MCO) Gemini Integration Quietly Redefining Its Edge In AI-Driven Credit Workflows?

Moody’s Corporation recently made its connected intelligence available within Google Cloud’s Gemini Enterprise for Financial Services via the Moody’s Credit Model Context Protocol server, giving users direct access to Moody’s credit ratings, research, and risk data inside their existing workflows. This deeper integration into a major cloud-based AI platform highlights Moody’s push to embed its risk intelligence directly into the tools financial professionals already use, potentially...
NYSE:CRI
NYSE:CRILuxury

Carter's (CRI) Stock May Be 16% Undervalued As Cash Flow Holds Up

Carter's stock has delivered a steep 60.0% decline over the past five years, yet valuation checks now suggest the market price may be lagging an intrinsic value estimate that screens the shares as undervalued. The question for investors is whether the current discount is justified by business risks or whether the market has become too pessimistic. The share price is down 60.0% over five years, which implies the market has materially reduced its expectations for Carter's. Future cash flow...
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

Why RUM Group (RUM) Is Up 13.6% After Announcing A $13.7 Billion AI GPU Deal

Earlier this month, RUM Group Inc. announced a six-year, approximately US$13.70 billion agreement to provide GPU services and AI chip infrastructure to an unnamed U.S.-based cloud customer from its under-development Maysville, Georgia facility, alongside warrants for the customer to purchase over 50 million Class A shares. An important angle for investors is that RUM Group currently lacks the financing to deliver on this very large contract, meaning the agreement’s value is closely tied to...
NYSE:AGCO
NYSE:AGCOMachinery

Is AGCO (AGCO) Below Fair Value On Its Farm Progress Show Product Reveal?

AGCO’s Farm Progress Show reveal puts new equipment in focus AGCO (AGCO) is drawing fresh attention after announcing a wide slate of new tractors, planters and precision retrofit solutions for its Fendt, Massey Ferguson and PTx brands ahead of the 2026 Farm Progress Show. See our latest analysis for AGCO. AGCO’s Farm Progress Show plans come as the stock has seen a mixed pattern, with the 7 day share price return of 10.41% and the 30 day share price return down 9.14%, while the 1 year total...
NasdaqGS:HQY
NasdaqGS:HQYHealthcare

HealthEquity (HQY) Is Getting Attention, So What Is The Market Watching?

Analysts expect HealthEquity (HQY) to report quarterly earnings of $1.19 per share and revenue of $350.23 million in its upcoming release, with projections indicating growth in custodial revenue and total HSA assets. See our latest analysis for HealthEquity. HealthEquity’s recent momentum has been firm, with a 30-day share price return of 11.38% and a 90-day share price return of 20.80%. The 1-year total shareholder return of 20.57% highlights how expectations around earnings and HSA growth...